Source: Pharmacy Times articles
The combination yielded superior progression-free (PFS) survival compared with standard of care.
Read More
Recent Content
- Correction: Chen et al. The Efficacy and Safety of Tandem Transplant Versus Single Stem Cell Transplant for Multiple Myeloma Patients: A Systematic Review and Meta-Analysis. Diagnostics 2024, 14, 1030
- Comparison of Standard of Care with or Without a PD-1/PD-L-1 Inhibitor for the Treatment of Multiple Myeloma: A Systematic Review and Meta-Analysis of Phase II and III Randomized Controlled Trials
- Combo treatment may offer new hope to astrocytoma patients: Trial
- Reduced-versus Standard-dose Melphalan as Single-agent Conditioning Regimen in Auto HSCT for Multiple Myeloma: A Systematic Review and Meta-Analysis
- Dosing begins in trial testing Enhertu for ovarian cancer
- (no title)
- (no title)
- Teclistamab combo improves relapsed, refractory myeloma outcomes
- Safety and Efficacy of Anti-B-cell Maturation Antigen (Anti-BCMA) Bispecific Antibodies for Relapsed/Refractory Multiple Myeloma: A Systematic Review of Clinical Trials
- (no title)